BlueWillow Biologics® is a clinical-stage biotechnology company that has developed a best-in-class, intranasal adjuvant and antigen delivery platform technology enabling a broad array of intranasal vaccine candidates. The platform has been shown to be safe in the over 400 humans dosed to date in human clinical trials. Originally discovered at the University of Michigan, the proprietary technology employs novel oil-in-water emulsion droplets approximately 400nm in size to adjuvant a robust mucosal, systemic and cellular immune response that is Th1 biased. The adjuvant is compatible with a broad range of antigens. This unique vaccine technology enables enhanced permeation of the nasal mucosal without penetration into the CNS and efficient presentation of antigens to the antigen presenting cells of the nasopharynx.